Your browser is no longer supported. Please, upgrade your browser.
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.47 Insider Own10.83% Shs Outstand74.52M Perf Week17.45%
Market Cap426.25M Forward P/E- EPS next Y-0.87 Insider Trans-0.25% Shs Float66.72M Perf Month61.13%
Income-34.40M PEG- EPS next Q-0.16 Inst Own20.20% Short Float4.38% Perf Quarter40.89%
Sales31.40M P/S13.57 EPS this Y65.20% Inst Trans- Short Ratio2.31 Perf Half Y276.32%
Book/sh1.09 P/B5.25 EPS next Y-48.60% ROA-28.10% Target Price3.63 Perf Year163.59%
Cash/sh0.88 P/C6.50 EPS next 5Y7.33% ROE-37.90% 52W Range1.42 - 6.25 Perf YTD55.43%
Dividend- P/FCF- EPS past 5Y24.50% ROI-44.10% 52W High-10.24% Beta2.03
Dividend %- Quick Ratio3.60 Sales past 5Y192.40% Gross Margin- 52W Low295.07% ATR0.49
Employees93 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)72.87 Volatility16.26% 11.36%
OptionableYes Debt/Eq0.03 EPS Q/Q58.10% Profit Margin- Rel Volume2.21 Prev Close5.72
ShortableYes LT Debt/Eq0.03 EarningsDec 12 AMC Payout- Avg Volume1.26M Price5.61
Recom2.30 SMA2038.54% SMA5048.74% SMA200110.82% Volume2,714,688 Change-1.92%
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $3
Nov-27-17Upgrade Piper Jaffray Neutral → Overweight
Sep-18-17Upgrade William Blair Mkt Perform → Outperform
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Nov-30-16Downgrade Piper Jaffray Overweight → Neutral
Nov-30-16Downgrade Chardan Capital Markets Buy → Neutral $8 → $2
Nov-30-16Downgrade Cantor Fitzgerald Buy → Hold
Nov-10-16Reiterated Chardan Capital Markets Buy $10 → $8
Aug-18-16Initiated Cantor Fitzgerald Buy $15
May-19-16Initiated Chardan Capital Markets Buy $12
Sep-25-15Reiterated Piper Jaffray Overweight $12 → $20
Oct-09-14Downgrade RBC Capital Mkts Outperform → Sector Perform $35 → $9
Mar-05-14Initiated RBC Capital Mkts Outperform $35
Mar-05-14Initiated Deutsche Bank Buy $45
Feb-26-13Initiated Dawson James Buy $4
Jan-11-18 03:51PM  Here's Why Arrowhead Pharmaceuticals Inc. Is Up Today Motley Fool +14.55%
Dec-27-17 04:00PM  Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors Business Wire
Dec-26-17 08:43AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017 Capital Cube
Dec-25-17 11:41AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : December 25, 2017 Capital Cube
Dec-22-17 03:57PM  What Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today Motley Fool +9.76%
07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV Business Wire
Dec-20-17 07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT Business Wire +5.21%
Dec-18-17 06:27PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4) Business Wire
07:20AM  Blog Exposure - FDA Approves Aclaris Therapeutics' ESKATA Topical Solution for Treatment of Common Skin Growths ACCESSWIRE
Dec-14-17 11:29AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: 2017 By the Numbers : December 14, 2017 Capital Cube -7.35%
Dec-13-17 07:38PM  Edited Transcript of ARWR earnings conference call or presentation 12-Dec-17 9:30pm GMT Thomson Reuters StreetEvents
07:00AM  3 Stocks to Watch on Wednesday: Arrowhead Pharmaceuticals Inc (ARWR), VeriFone Systems Inc (PAY) and Streamline Health Solutions Inc. (STRM) InvestorPlace
Dec-12-17 12:46PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : December 12, 2017 Capital Cube
Dec-06-17 04:00PM  ARWR: New HBV Clinical Data of ARC-520 Presented at HEP DART Meeting Zacks Small Cap Research
11:40AM  Arrowhead Pharma Wins in Midstage Hepatitis Study 24/7 Wall St.
07:00AM  Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy Business Wire
Dec-05-17 04:00PM  Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results Business Wire
Nov-30-17 01:25PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 30, 2017 Capital Cube
08:20AM  Todays Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Array BioPharma Inc. ACCESSWIRE
Nov-14-17 07:30AM  Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-13-17 08:20AM  Analysis: Positioning to Benefit within Catabasis, Flowserve, MGIC Investment, Arrowhead, Silver Spring, and Live Nation Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-03-17 11:53AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 3, 2017 Capital Cube
Oct-23-17 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
08:00AM  Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017 Business Wire
Oct-16-17 09:48AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 16, 2017 Capital Cube
Oct-10-17 09:30AM  Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting® Business Wire -8.49%
Oct-03-17 04:00PM  Arrowhead to Present at Chardan Gene Therapy Conference Business Wire
Oct-02-17 10:40AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
Sep-27-17 02:00PM  Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment Business Wire +7.92%
Sep-15-17 12:06PM  Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today Motley Fool +18.28%
08:00AM  Today's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals ACCESSWIRE
Sep-14-17 12:00PM  Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM Platform and Lead RNAi-based Drug Candidates Business Wire -20.96%
Sep-11-17 09:00PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : September 12, 2017 Capital Cube +10.29%
04:00PM  Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-08-17 04:34PM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2017 By the Numbers : September 8, 2017 Capital Cube -6.04%
Sep-01-17 07:30AM  Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies Business Wire
Aug-13-17 08:31PM  Edited Transcript of ARWR earnings conference call or presentation 3-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-17 08:10AM  Todays Research Reports on Stocks to Watch: Horizon Pharma and Arrowhead Pharmaceuticals ACCESSWIRE -5.88%
Aug-03-17 04:00PM  Arrowhead Reports Fiscal 2017 Third Quarter Results Business Wire
11:50AM  Investor Network: Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-27-17 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results Business Wire
Jul-10-17 01:59PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : July 10, 2017 Capital Cube
Jun-09-17 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
May-26-17 12:58PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 26, 2017 Capital Cube
May-16-17 12:46PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 16, 2017 Capital Cube
May-06-17 08:10PM  Edited Transcript of ARWR earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-05-17 03:50PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 5, 2017 Capital Cube
11:10AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017 Capital Cube
08:00AM  Today's Research Reports on Arrowhead Pharmaceuticals and Paratek Pharmaceuticals Post Earnings Accesswire
May-03-17 04:00PM  Arrowhead Reports Fiscal 2017 Second Quarter Results Business Wire
Apr-26-17 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results Business Wire
Apr-24-17 07:30AM  Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress Business Wire
Apr-20-17 11:30AM  Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress Business Wire
Apr-19-17 02:10PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : April 19, 2017 Capital Cube
Apr-05-17 07:30AM  Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress Business Wire
07:30AM  Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress
Mar-27-17 03:49PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
03:49PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : March 27, 2017
Mar-23-17 07:38AM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification
07:30AM  Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement Business Wire
Mar-21-17 11:32AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q1, 2017 By the Numbers : March 21, 2017 Capital Cube -7.11%
11:32AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q1, 2017 By the Numbers : March 21, 2017
Feb-27-17 10:00AM  SBPH: 2016 Results Sustaining Continued HBV/STING Development Zacks Small Cap Research +9.77%
10:00AM  SBPH: 2016 Results Sustaining Continued HBV/STING Development
Feb-16-17 01:34PM  These 5 Stocks Under $10 Could Explode Higher TheStreet.com
01:34PM  These 5 Stocks Under $10 Could Explode Higher
Feb-10-17 01:04PM  ARROWHEAD PHARMACEUTICALS, INC. Financials
Feb-06-17 05:42PM  Edited Transcript of ARWR earnings conference call or presentation 6-Feb-17 9:30pm GMT Thomson Reuters StreetEvents
05:42PM  Edited Transcript of ARWR earnings conference call or presentation 6-Feb-17 9:30pm GMT
04:15PM  ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
04:06PM  Arrowhead Research reports 1Q loss Associated Press
04:06PM  Arrowhead Research reports 1Q loss
04:00PM  Arrowhead Reports Fiscal 2017 First Quarter Results Business Wire
07:07AM  Q1 2017 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on Arrowhead Pharmaceuticals and Jaguar Animal Health Accesswire -10.31%
Jan-30-17 04:01PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results Business Wire
Jan-20-17 07:51PM  Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action Business Wire
Jan-14-17 06:25PM  IMPORTANT ARWR SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Jan-13-17 05:41PM  SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead Pharmaceuticals, Inc. and Certain Officers ARWR GlobeNewswire -5.07%
11:01AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 ARWR GlobeNewswire
Jan-12-17 11:00AM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) and Lead Plaintiff Deadline: January 16, 2017 GlobeNewswire
09:42AM  These 3 Biotech Stocks Are Already Moving Wildly on Thursday
Jan-10-17 10:51AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire +6.88%
Jan-09-17 12:27PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 ARWR Business Wire
09:50AM  Mondays 4 Biggest Biopharma Movers
04:06AM  Arrowhead Provides Response to New Minority Shareholder Announcement Business Wire
Jan-07-17 06:00AM  DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm Business Wire
Jan-06-17 04:45PM  ARWR LOSS NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ARWR GlobeNewswire +22.50%
Jan-05-17 05:25AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -5.33%
Jan-04-17 10:13AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) and Lead Plaintiff Deadline: January 16, 2017 Accesswire
Jan-03-17 03:22PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire +8.39%
12:30PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : January 3, 2017
11:26AM  ARWR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Arrowhead Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 Business Wire
Dec-28-16 11:37AM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:38AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) and Lead Plaintiff Deadline: January 16, 2017 Accesswire
Dec-27-16 02:22PM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
12:51PM  ARWR INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of Commencement of a Class Action Involving Arrowhead Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 PR Newswire
Dec-23-16 06:20PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire +16.06%
04:42PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. - ARWR GlobeNewswire
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GIVEN BRUCE DChief Operating OfficerJan 01Sale3.6920,00073,800928,356Jan 03 07:25 PM